David Trent

4.6k total citations · 3 hit papers
27 papers, 3.8k citations indexed

About

David Trent is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, David Trent has authored 27 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 11 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David Trent's work include Lung Cancer Treatments and Mutations (6 papers), Pancreatic function and diabetes (5 papers) and Lung Cancer Research Studies (4 papers). David Trent is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Pancreatic function and diabetes (5 papers) and Lung Cancer Research Studies (4 papers). David Trent collaborates with scholars based in United States, Germany and Canada. David Trent's co-authors include Gordon C. Weir, Susan Bonner‐Weir, Joan H. Schiller, Thomas J. Smith, John R. Strawn, Gregory A. Masters, Sarah Temin, Christopher G. Azzoli, Giuseppe Giaccone and Julie R. Brahmer and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

David Trent

27 papers receiving 3.7k citations

Hit Papers

American Society of Clinical Oncology Clinical Practice G... 2007 2026 2013 2019 2009 2007 2015 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
    2009 752 citations Christopher G. Azzoli, Sherman Baker et al. Journal of Clinical Oncology profile →
  2. American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer
    2007 723 citations Gary H. Lyman, Alok A. Khorana et al. Journal of Clinical Oncology profile →
  3. Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
    2015 695 citations Gregory A. Masters, Sarah Temin et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Trent United States 19 1.5k 1.5k 872 793 630 27 3.8k
Leo R. Zacharski United States 39 836 0.6× 825 0.6× 699 0.8× 512 0.6× 1.2k 1.9× 141 4.6k
Tom R. Fitch United States 34 1.3k 0.9× 2.0k 1.4× 1.2k 1.3× 763 1.0× 123 0.2× 97 4.6k
D C Tormey United States 32 718 0.5× 2.1k 1.4× 561 0.6× 388 0.5× 185 0.3× 55 3.6k
James R. Rigas United States 39 3.3k 2.2× 3.4k 2.3× 2.2k 2.5× 368 0.5× 341 0.5× 142 6.5k
F. Lofts United Kingdom 18 4.5k 3.0× 1.8k 1.2× 545 0.6× 3.1k 3.9× 270 0.4× 45 6.3k
Roger Keresztes United States 19 631 0.4× 1.1k 0.7× 655 0.8× 337 0.4× 242 0.4× 37 2.7k
Nissim Haim Israel 37 1.1k 0.7× 1.2k 0.8× 598 0.7× 453 0.6× 193 0.3× 155 3.8k
Frederick R. Ahmann United States 27 2.6k 1.7× 804 0.5× 668 0.8× 502 0.6× 44 0.1× 65 3.9k
Albert Abad Spain 28 1.6k 1.1× 2.5k 1.7× 1.2k 1.4× 489 0.6× 299 0.5× 84 4.2k
Roscoe F. Morton United States 35 1.9k 1.3× 4.6k 3.1× 2.0k 2.3× 899 1.1× 121 0.2× 97 7.8k

Countries citing papers authored by David Trent

Since Specialization
Citations

This map shows the geographic impact of David Trent's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Trent with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Trent more than expected).

Fields of papers citing papers by David Trent

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Trent. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Trent. The network helps show where David Trent may publish in the future.

Co-authorship network of co-authors of David Trent

This figure shows the co-authorship network connecting the top 25 collaborators of David Trent. A scholar is included among the top collaborators of David Trent based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Trent. David Trent is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Masters, Gregory A., Sarah Temin, Christopher G. Azzoli, et al.. (2015). Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology. 33(30). 3488–3515. 695 indexed citations breakdown →
2.
3.
Raefsky, Eric, David R. Spigel, J. R. Infante, et al.. (2011). Phase II study of NK012 in relapsed small cell lung cancer.. Journal of Clinical Oncology. 29(15_suppl). 7079–7079. 12 indexed citations
4.
Azzoli, Christopher G., Sarah Temin, Timothy Aliff, et al.. (2011). 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 29(28). 3825–3831. 234 indexed citations
5.
Hainsworth, John D., Jeffrey R. Infante, David R. Spigel, et al.. (2010). Bevacizumab and everolimus in the treatment of patients with metastatic melanoma. Cancer. 116(17). 4122–4129. 62 indexed citations
6.
Azzoli, Christopher G., Sherman Baker, Sarah Temin, et al.. (2010). [American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer].. PubMed. 13(3). 171–89. 48 indexed citations
7.
Azzoli, Christopher G., Sherman Baker, Sarah Temin, et al.. (2009). American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 27(36). 6251–6266. 752 indexed citations breakdown →
8.
Socinski, Mark A., Mansoor N. Saleh, David Trent, et al.. (2009). A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC). Annals of Oncology. 20(6). 1068–1073. 34 indexed citations
9.
Peyton, James D., David R. Spigel, Howard A. Burris, et al.. (2009). Phase II trial of bevacizumab and everolimus in the treatment of patients with metastatic melanoma: Preliminary results. Journal of Clinical Oncology. 27(15_suppl). 9027–9027. 9 indexed citations
10.
Saleh, Mansoor N., Mark A. Socinski, David Trent, et al.. (2007). Randomized phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 25(18_suppl). 7586–7586. 5 indexed citations
11.
Lyman, Gary H., Alok A. Khorana, Anna Falanga, et al.. (2007). American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer. Journal of Clinical Oncology. 25(34). 5490–5505. 723 indexed citations breakdown →
12.
Khong, Hoa, Luke Dreisbach, Hedy L. Kindler, et al.. (2007). A phase 2 study of ARQ 501 in combination with gemcitabine in adult patients with treatment naïve, unresectable pancreatic adenocarcinoma. Journal of Clinical Oncology. 25(18_suppl). 15017–15017. 34 indexed citations
13.
Trent, David, Richard L. Seither, & I. David Goldman. (1991). Compartmentation of intracellular folates. Biochemical Pharmacology. 42(5). 1015–1019. 22 indexed citations
14.
15.
Seither, Richard L., et al.. (1989). Folate-Pool Interconversions and Inhibition of Biosynthetic Processes after Exposure of L1210 Leukemia Cells to Antifolates. Journal of Biological Chemistry. 264(29). 17016–17023. 55 indexed citations
16.
Trent, David, et al.. (1984). Pancreatic and Gut Hormones during Fasting: Insulin, Glucagon, and Somatostatin. Hormone Research. 19(2). 70–76. 11 indexed citations
17.
Bonner‐Weir, Susan, David Trent, & Gordon C. Weir. (1983). Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release.. Journal of Clinical Investigation. 71(6). 1544–1553. 379 indexed citations
18.
Fletcher, Donald J., David Trent, & Gordon C. Weir. (1983). Catfish somatostatin is unique to piscine tissues. Regulatory Peptides. 5(2). 181–187. 9 indexed citations
19.
Bonner‐Weir, Susan, et al.. (1981). Limited B cell regeneration in a B cell deficient rat model: Studies with dexamethasone. Metabolism. 30(9). 914–918. 31 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Leo R. Zacharski Breakdown of academic impact, for papers by Tom R. Fitch Breakdown of academic impact, for papers by D C Tormey Breakdown of academic impact, for papers by James R. Rigas Breakdown of academic impact, for papers by F. Lofts Breakdown of academic impact, for papers by Roger Keresztes Breakdown of academic impact, for papers by Nissim Haim Breakdown of academic impact, for papers by Frederick R. Ahmann Breakdown of academic impact, for papers by Albert Abad Breakdown of academic impact, for papers by Roscoe F. Morton
Rankless by CCL
2026